insights_auto
SGIOY کی میں اضافہ کیوں ہوا 3.76%?
گہرائی سے تحقیق کریںchevron_right
SGIOY:OTCMKTS
Shionogi 2 ADR Representing 1 Ord Shs
$9.10
arrow_upward
+3.76%(+0.33) 1 دن
15 اکتوبر, 2:43:10 PM GMT -4 · USD
search
تمام علامات
| علامت | قیمت | تبدیلی | % تبدیلی |
|---|
insights_autoSGIOY کے لیے سرفہرست بصیرتیں تخلیق کی جا رہی ہیں...
کھولیں
$9.53
اعلی
$9.53
کم
$8.95
مارکیٹ کی سرمایہ کاری
25.75 کھرب
اوسط والیوم
1.73 لاکھ
والیوم
68.12 ہزار
52 ہفتے میں اعلی
$12.00
52 ہفتے کا کم
$7.83
بی ٹا
0.07
بقایہ شیئرز
1.78 ارب
ملازمین کی تعداد
6 ہزار
کھولیں
$9.53
اعلی
$9.53
کم
$8.95
مارکیٹ کی سرمایہ کاری
25.75 کھرب
اوسط والیوم
1.73 لاکھ
والیوم
68.12 ہزار
52 ہفتے میں اعلی
$12.00
52 ہفتے کا کم
$7.83
بی ٹا
0.07
بقایہ شیئرز
1.78 ارب
ملازمین کی تعداد
6 ہزار
خبریں اور کہانیاں
ویب ذرائع اور خبروں کے پارٹنرز سے
The Seattle Times
·
1 گھنٹہ پہلے
Wall Street steadies following jarring drops for AI stocks worldwide
Opening Bell Daily
·
2 منٹ پہلے
S&P 500 Fourth-Quarter Returns Are Strongest in Midterm Years
Simply Wall Street
·
17 منٹ پہلے
Super Micro Computer (SMCI) Deepens AI Push With OCP Expansion And New Inference Tie Up
پروفائل
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
Shionogi 2 ADR Representing 1 Ord Shs کے بارے میں